Etanercept or Methotrexate Withdrawal in Rheumatoid Arthritis Patients in Sustained Remission.
Jeffrey R CurtisPaul EmeryElaine KarisBoulos HaraouiVivian P BykerkPriscilla K YenGreg KricorianJames B ChungPublished in: Arthritis & rheumatology (Hoboken, N.J.) (2021)
The efficacy of etanercept monotherapy was superior to that of methotrexate monotherapy and similar to that of combination therapy in maintaining remission in patients with RA. SDAI-defined remission was recaptured in most of the patients who were given rescue therapy. These data could inform decision-making when withdrawal of therapy is being considered to reduce treatment burden in patients with well-controlled RA.
Keyphrases
- disease activity
- rheumatoid arthritis patients
- combination therapy
- rheumatoid arthritis
- systemic lupus erythematosus
- ankylosing spondylitis
- juvenile idiopathic arthritis
- decision making
- high dose
- randomized controlled trial
- clinical trial
- machine learning
- stem cells
- big data
- risk factors
- ulcerative colitis
- idiopathic pulmonary fibrosis
- cell therapy
- mesenchymal stem cells
- systemic sclerosis
- bone marrow